Intravenous buprenorphine/naloxone and concomitant oral pregabalin misuse: a case report

Creative Commons License

KULAKSIZOĞLU B., Kara H., BODUR B., Kuloglu M.

NEUROPSYCHIATRIC DISEASE AND TREATMENT, vol.14, pp.3033-3035, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 14
  • Publication Date: 2018
  • Doi Number: 10.2147/ndt.s179688
  • Journal Name: NEUROPSYCHIATRIC DISEASE AND TREATMENT
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.3033-3035
  • Keywords: intravenous buprenorphine-naloxone, pregabalin, drug misuse, opioid addiction, DRUG-USERS, ABUSE, DEPENDENCE, NALOXONE, FRANCE
  • Open Archive Collection: AVESIS Open Access Collection
  • Akdeniz University Affiliated: Yes

Abstract

Opioid misuse and dependence are major medical and social concerns worldwide. Buprenorphine/naloxone combination (BNC) is a drug that has misuse potential and is used to treat opioid dependence, including buprenorphine and naloxone. Buprenorphine shows its pharmacological effects by binding to opioid receptors. Buprenorphine is a partial agonist and has smaller maximal effects compared to those of full agonists (heroin, methadone). Naloxone is a non-selective opiate antagonist added to buprenorphine for the prevention of intravenous diversion. BNC is used in the treatment of opioid dependence for detoxification and maintenance. The drug should be used as a sublingual film tablet. Pregabalin is used in the treatment of neuropathic pain, epilepsy and anxiety disorders. It is increasingly being reported as possessing a potential for misuse. In this article, we present a case of intravenous BNC and concomitant oral pregabalin misuse that developed in a monitored and treated patient for the reason of opioid dependence.